Induced psoriasiform eruption, especially by anti-tumor necrosis factor alpha, was a rather rare event but nowadays cases are increasing because of its prescription for many different diseases. There are several clinical forms; one example is the pustulosis form presented in this case report.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Psoriasiform Dermatitis Following Kawasaki Disease: A Case Report and Literature Review.
Pediatr Dermatol
December 2024
Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Kawasaki disease (KD) is an idiopathic acute inflammatory illness that commonly affects children in Northeast Asian countries. In this case report, a psoriasiform eruption appeared on the face and extremities following the onset of KD. A review of previous reports identified 38 cases of psoriasiform eruptions following KD, typically appearing 4 days to 2 months after the onset of KD, unlike other skin manifestations associated with the disease.
View Article and Find Full Text PDFCytokine Profiling of Erythroderma Biopsies Reveals Types 2 and 17 Immune Activation Status.
J Cutan Pathol
December 2024
Department of Dermatology and Pathology, University of California, California, USA.
Background: Erythroderma is a dermatologic condition characterized by widespread red and scaly skin. The causes include, but are not limited to, psoriasis, eczema, drug eruptions, pityriasis rubra pilaris (PRP), and cutaneous T-cell lymphoma. Most of these are typified by Type 2 (e.
View Article and Find Full Text PDFDermatoses in patients with inflammatory bowel disease under tumor necrosis factor-alpha inhibitors treatment.
Med Clin (Barc)
November 2024
Postgraduate Program in Sciences Applied to Adult Health, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil; Departamento de Clínica Médica, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil. Electronic address:
Introduction: Tumor necrosis factor-alpha inhibitor (anti-TNF-α) agents are essential in treating inflammatory bowel diseases (IBD). Their use, however, may cause dermatoses. This study aims to characterize the dermatoses in IBD patients on anti-TNF-α therapy.
View Article and Find Full Text PDFParadoxical Psoriasiform Skin Eruption in Pediatric Patients with Inflammatory Bowel Disease Treated with TNFα Inhibitors.
Clin Exp Dermatol
October 2024
School of Medicine, Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
Article Synopsis
- TNFα inhibitors (TNFαI) can cause skin reactions resembling psoriasis in children with inflammatory bowel diseases (IBD), although most research focuses on adults.
- In a study involving 454 pediatric IBD patients, 12.8% developed these eruptions, with a median age of 14.1 years and an average of 15 months post-treatment initiation for eruptions to appear.
- Treatment commonly involved topical steroids, but one-third of the patients required more intense interventions, and some needed to stop TNFαI treatment altogether, highlighting the need for a collaborative treatment strategy.
Psoriasiform drug eruption: A case series with a review of the literature.
Exp Dermatol
September 2024
Department of Dermatology, Tokyo Medical University, Shinjuku-ku, Tokyo, Japan.
The present case series examined five instances of psoriasiform drug eruption diagnosed between 2014 and 2022 at the study site and 23 cases of drug eruption manifesting psoriasiform lesions which had been reported between 1986 and 2022. The causative drug, distribution of the skin eruptions, clinical latency to eruption, treatment course, and histopathological findings were investigated. The most common causative agents were calcium channel blockers (CCB) (64.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!